Eric Coldwell
Stock Analyst at Robert W. Baird
(4.60)
# 931
Out of 4,994 analysts
796
Total ratings
58.5%
Success rate
7.7%
Average return
Main Sectors:
Stocks Rated by Eric Coldwell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AHCO AdaptHealth | Reiterated: Buy | $10 → $9 | $5.77 | +55.98% | 43 | Sep 17, 2026 | |
| ACH Accendra Health | Downgraded: Hold | $6 → $1.5 | $0.85 | +76.47% | 73 | Aug 11, 2026 | |
| COR Cencora | Reiterated: Buy | $339 → $370 | $314.43 | +17.67% | 75 | Aug 6, 2026 | |
| CRL Charles River Laboratories International | Reiterated: Buy | $213 → $291 | $285.11 | +2.07% | 71 | Aug 6, 2026 | |
| MCK McKesson | Reiterated: Buy | $941 → $1,015 | $891.23 | +13.89% | 78 | Aug 6, 2026 | |
| MDLN Medline | Reiterated: Buy | $45 → $42 | $34.43 | +21.99% | 4 | Aug 6, 2026 | |
| ICLR ICON Public Limited Company | Reiterated: Buy | $186 → $194 | $167.11 | +16.09% | 71 | Jul 31, 2026 | |
| LH Labcorp Holdings | Reiterated: Buy | $334 → $352 | $311.54 | +12.99% | 74 | Jul 31, 2026 | |
| FTRE Fortrea Holdings | Reiterated: Buy | $20 → $23 | $20.43 | +12.58% | 15 | Jul 30, 2026 | |
| IQV IQVIA Holdings | Reiterated: Buy | $249 → $287 | $270.09 | +6.26% | 68 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $236 → $255 | $234.76 | +8.62% | 61 | Jul 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $547 → $624 | $630.19 | -0.98% | 60 | Jul 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $252 → $248 | $222.04 | +11.69% | 69 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $110 | $87.10 | n/a | 28 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $23 → $22 | $4.85 | n/a | 6 | May 9, 2014 |
AdaptHealth
Sep 17, 2026
Reiterated: Buy
Price Target: $10 → $9
Current: $5.77
Upside: +55.98%
Accendra Health
Aug 11, 2026
Downgraded: Hold
Price Target: $6 → $1.5
Current: $0.85
Upside: +76.47%
Cencora
Aug 6, 2026
Reiterated: Buy
Price Target: $339 → $370
Current: $314.43
Upside: +17.67%
Charles River Laboratories International
Aug 6, 2026
Reiterated: Buy
Price Target: $213 → $291
Current: $285.11
Upside: +2.07%
McKesson
Aug 6, 2026
Reiterated: Buy
Price Target: $941 → $1,015
Current: $891.23
Upside: +13.89%
Medline
Aug 6, 2026
Reiterated: Buy
Price Target: $45 → $42
Current: $34.43
Upside: +21.99%
ICON Public Limited Company
Jul 31, 2026
Reiterated: Buy
Price Target: $186 → $194
Current: $167.11
Upside: +16.09%
Labcorp Holdings
Jul 31, 2026
Reiterated: Buy
Price Target: $334 → $352
Current: $311.54
Upside: +12.99%
Fortrea Holdings
Jul 30, 2026
Reiterated: Buy
Price Target: $20 → $23
Current: $20.43
Upside: +12.58%
IQVIA Holdings
Jul 29, 2026
Reiterated: Buy
Price Target: $249 → $287
Current: $270.09
Upside: +6.26%
Jul 24, 2026
Reiterated: Hold
Price Target: $236 → $255
Current: $234.76
Upside: +8.62%
Jul 24, 2026
Reiterated: Hold
Price Target: $547 → $624
Current: $630.19
Upside: -0.98%
May 1, 2026
Reiterated: Buy
Price Target: $252 → $248
Current: $222.04
Upside: +11.69%
Apr 18, 2022
Reiterated: Hold
Price Target: $110
Current: $87.10
Upside: n/a
May 9, 2014
Rated: Buy
Price Target: $23 → $22
Current: $4.85
Upside: n/a